Cargando…

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis

OBJECTIVE: To evaluate the predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis (RA). METHODS: A post hoc analysis was performed on a prospective 2-year study of 59 patients with active RA starting on antitumour necrosis factor (TNF). Tenderness and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Peter P, Mari, Karine, Devauchelle-Pensec, Valérie, Jousse-Joulin, Sandrine, D'Agostino, Maria Antonietta, Chalès, Gérard, Gaudin, Philippe, Mariette, Xavier, Saraux, Alain, Dougados, Maxime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800805/ https://www.ncbi.nlm.nih.gov/pubmed/27042336 http://dx.doi.org/10.1136/rmdopen-2015-000205

Ejemplares similares

Diagnostic impact of routine Lyme serology in recent-onset arthritis: results from the ESPOIR cohort
por: Guellec, Dewi, et al.
Publicado: (2016)

Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR)
por: Gandjbakhch, Frederique, et al.
Publicado: (2017)

The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound
por: Dougados, Maxime, et al.
Publicado: (2013)

Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort
por: Guellec, Dewi, et al.
Publicado: (2015)

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis
por: Gossec, Laure, et al.
Publicado: (2015)

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis
por: Diekhoff, Torsten, et al.
Publicado: (2019)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure
por: Rivellese, F., et al.
Publicado: (2020)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
por: Seror, Raphaele, et al.
Publicado: (2022)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
por: Saraux, Alain, et al.
Publicado: (2020)

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
por: Kvien, Tore K, et al.
Publicado: (2020)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study
por: Nguyen, Yann, et al.
Publicado: (2022)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Reduced cardiorespiratory fitness is a mediator of excess all-cause mortality in rheumatoid arthritis: the Trøndelag Health Study
por: Liff, Marthe Halsan, et al.
Publicado: (2021)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Relative importance of inflammation and cardiorespiratory fitness for all-cause mortality risk in persons with rheumatoid arthritis: the population-based Trøndelag Health Study
por: Videm, Vibeke, et al.
Publicado: (2023)

Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity
por: Liff, Marthe Halsan, et al.
Publicado: (2019)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting
por: Delteil, Alycia, et al.
Publicado: (2023)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

Lymphoma complicating rheumatoid arthritis: results from a French case–control study
por: Kedra, Joanna, et al.
Publicado: (2021)

Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis
por: Perpétuo, Inês Pedro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jgv7r9rakjprhoo5j8i5m2kul5